Option chain shows key data for XS Financial Inc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for XS Financial Inc.

XS Financial Inc (OTC:XSHLF) Stock, Option Chain

Image created using artificial intelligence tools

Cannabis

Earnings

News

Penny Stocks

Markets

XSHLF

CSE:XSF

XS Financial Inc. (CSE: XSF) (OTCQB: XSHLF), a specialty finance company providing CAPEX and equipment financing solutions to cannabis companies in the U.S. reported robust financial performance for Q3 ending September 30th, 2023.

Los Angeles Finance Co. Achieves Record Q3 Performance, Generates $209.6M, Eyes Strategic Growth In 2024

Financing

XS Financial Inc. (CSE: XSF) (OTCQB: XSHLF) has entered into a $15 million line of credit with bank lenders.

Los Angeles Finance Co. To Fund Expansion Projects In Cannabis Sector With $15M Credit Line

UGRO

Urban-gro, Inc. (NASDAQ: UGRO) entered into an agreement related to its investment in a private placement convertible note with XS Financial Inc (CSE: XSF) (OTCQB: XSHLF), an equipment finance company to the US cannabis

Cashing In On Cannabis: Urban-gro Secures Over $2M In Deal With XS Financial, What&#39;s Next?

XS Financial Inc

DLTR

Apollo Global, Sycamore And Brigade Capital Are Competing To Acquire Family Dollar

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Neutral and raises the price target from $206 to $215.

Price Target

Analyst Ratings

KRYS

Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $215

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and raises the price target from $81 to $82.

BMRN

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Raises Price Target to $82

WIIM

ARES

DOMH

EMCG

FCNCA

HOOD

IBKR

RILY

ROOT

SOFI

STEP

Shares of companies within the broader financial sector are trading lower amid overall market weakness. Investors may be evaluating the risk of inflation as the retail sector shows early signs of a weaker consumer.

Citigroup analyst Ronald Josey maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $275 to $280.

Citigroup Maintains Buy on Wix.com, Raises Price Target to $280

Citigroup analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and lowers the price target from $67 to $64.

IONS

Citigroup Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $64

E-commerce company&nbsp;Etsy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43813431/e-commerce-company-etsy-q4-earnings-sales-miss-pressured-consumer-spending-active-buyers-dip-and-more" rel="noreferrer noopener">fourth-quarter FY24 earnings yesterday</a>. The following are the opinions of different analysts on the same.
Needham analyst Bernie McTernan reiterated a B<a href="https://www.benzinga.com/quote/ETSY/analyst-ratings">uy rating on the shares and maintained a price forecast of $60.00</a>. In the fourth quarter, GMS fell short of expectations, primarily due to ongoing challenges in consumer discretionary spending, noted the analyst.
Additionally, the company chose to focus on long-term initiatives instead of short-term growth, along with a shorter holiday season. The shift to long-term investments is estimated to have impacted GMS by a few hundred million, but it also laid the groundwork for initiatives expected to drive growth in 2025, such as personalization, a new marketing mix, and app development.
The analyst is taking a more conservative approach to the GMS model, assuming only a slight improvement in the YoY declines in the second quarter, 4% YoY declines in the latter half of 2025 and &lt;1% GMS growth in &#8217;26E, considering this as a prudent approach given the uncertainty from leadership changes, strategic shifts, and ongoing macroeconomic pressures on consumer spending.
ETSY is boosting customer engagement and frequency through initiatives like gifting, quality improvements, a new loyalty program, and app investments.
Gifting sales in 2024 outperformed the broader marketplace, contributing 29% to total GMS. Although its still early, management is seeing promising signs of increased frequency and user engagement on Etsy Insider, noted the analyst.
For FY25E, the analyst lowers GMS estimates by -6% and FY25E adj. EBITDA estimates come down by ~10%. The challenges impacting e-commerce consumer spending have affected the entire sector, but the analyst notes Etsy has the opportunity to emerge stronger.
By leveraging the larger scale gained during the pandemic, Etsy can enhance the user experience, which should drive increased consideration for the marketplace and more frequent purchases, concluded the analyst.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43846469/walmart-q4-earnings-shine-but-soft-fy26-outlook-disappoints-street" rel="noreferrer noopener">Walmart Q4 Earnings Shine, But Soft FY26 Outlook Disappoints Street</a>
Canaccord Genuity analyst Maria Ripps maintains a Buy rating on the shares and lowers the price forecast from $105.00 to $76.00.
The analyst said that Etsy posted mixed results for the quarter, with active buyers, GMS, and revenue falling short of expectations, while take rate and profitability exceeded forecasts.
Marketplace activity was sluggish in October and November, and the company acknowledged that prioritizing foundational product development over short-term GMS drivers led to a GMS headwind of several hundred million, impacting the fourth quarter and first quarter.
However, Etsy returned to a more balanced product development strategy at the start of the year, expecting benefits to grow throughout 2025.
With strategic initiatives like expanding Gifting, boosting loyalty program adoption, improving personalization, and increasing app downloads, management anticipates improving GMS year-over-year trends.
Nevertheless, the first quarter is expected to be another tough quarter, with GMS declining similarly to the fourth quarter. Profitability expectations were slightly below forecasts, with margins expected to improve in the second half of 2025.
Despite pressure on Etsy shares, the stock now trades at about 3x FY25 revenue and 10x adjusted EBITDA, suggesting significant negative sentiment is already priced in.
If consumer discretionary spending rebounds and growth initiatives yield stronger results, investor confidence could recover, with further upside if the de minimis exemption is repealed and competition eases, noted the analyst.
Price Action: ETSY shares are trading lower by 1.47% at $50.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/02/43778605/tesla-files-fresh-lawsuit-against-matthews-after-court-defeat" target="_blank" rel="noreferrer noopener">Tesla Files Fresh Lawsuit Against Matthews After Court Defeat</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Reiteration

Trading Ideas

General

ETSY

Etsy Stock Declines Amid Q4 Shortfall But Long-Term Strategy Could Pay Off, Say Analysts

Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRSP, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for CRISPR Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 53%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $148,003, and 12 are calls, for a total amount of $571,849.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $75.0 for CRISPR Therapeutics over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CRISPR Therapeutics's big money trades within a strike price range of $40.0 to $75.0 over the last 30 days.
<h3>CRISPR Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740076245_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRSP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.95</td>
<td>$1.9</td>
<td>$1.9</td>
<td>$60.00</td>
<td>$76.0K</td>
<td>1.3K</td>
<td align="right">417</td>
</tr>
<tr>
<td>CRSP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.7</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$50.00</td>
<td>$62.5K</td>
<td>1.0K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CRSP</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$13.4</td>
<td>$11.1</td>
<td>$12.2</td>
<td>$47.50</td>
<td>$61.0K</td>
<td>59</td>
<td align="right">0</td>
</tr>
<tr>
<td>CRSP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$11.9</td>
<td>$11.7</td>
<td>$11.7</td>
<td>$40.00</td>
<td>$58.5K</td>
<td>571</td>
<td align="right">107</td>
</tr>
<tr>
<td>CRSP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$10.1</td>
<td>$9.5</td>
<td>$10.1</td>
<td>$40.00</td>
<td>$57.5K</td>
<td>180</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About CRISPR Therapeutics</h3>
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Following our analysis of the options activities associated with CRISPR Therapeutics, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of CRISPR Therapeutics</h3>
<ul>
<li>With a volume of 1,764,822, the price of CRSP is down -4.38% at $50.7. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 76 days.</li>
</ul>
<h3>What The Experts Say On CRISPR Therapeutics</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $73.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Underweight rating on CRISPR Therapeutics with a target price of $32. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on CRISPR Therapeutics, which currently sits at a price target of $120. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on CRISPR Therapeutics with a target price of $48. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $84. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on CRISPR Therapeutics, which currently sits at a price target of $82. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

CRSP

Market Whales and Their Recent Bets on CRSP Options

Whales with a lot of money to spend have taken a noticeably bullish stance on Wingstop.
Looking at options history for Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 11% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $164,302 and 5, calls, for a total amount of $399,890.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $400.0 for Wingstop, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Wingstop's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Wingstop's substantial trades, within a strike price spectrum from $240.0 to $400.0 over the preceding 30 days.
<h3>Wingstop 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740076240_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WING</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$62.0</td>
<td>$58.5</td>
<td>$60.85</td>
<td>$250.00</td>
<td>$152.1K</td>
<td align="right">7</td>
<td align="right">26</td>
</tr>
<tr>
<td>WING</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$27.4</td>
<td>$25.8</td>
<td>$26.5</td>
<td>$240.00</td>
<td>$145.7K</td>
<td align="right">17</td>
<td align="right">6</td>
</tr>
<tr>
<td>WING</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.9</td>
<td>$25.4</td>
<td>$25.4</td>
<td>$270.00</td>
<td>$63.5K</td>
<td align="right">209</td>
<td align="right">11</td>
</tr>
<tr>
<td>WING</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$19.8</td>
<td>$18.3</td>
<td>$19.5</td>
<td>$310.00</td>
<td>$48.7K</td>
<td align="right">116</td>
<td align="right">0</td>
</tr>
<tr>
<td>WING</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.2</td>
<td>$10.3</td>
<td>$10.5</td>
<td>$250.00</td>
<td>$40.9K</td>
<td align="right">328</td>
<td align="right">188</td>
</tr>
</tbody>
</table>

<h3>About Wingstop</h3>
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, reaching north of 2,200 global stores at the end of 2023, rendering Wingstop the 31st-largest restaurant brand in the US by system sales, according to Euromonitor data. With a 98% franchised model, Wingstop generates the lion share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
<h3>Where Is Wingstop Standing Right Now?</h3>
<ul>
<li>With a volume of 1,021,351, the price of WING is down -6.76% at $247.1. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>Expert Opinions on Wingstop</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $369.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Stephens &amp; Co. keeps a Overweight rating on Wingstop with a target price of $400. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Wingstop, targeting a price of $315. 
&#x2A; An analyst from TD Securities has decided to maintain their Buy rating on Wingstop, which currently sits at a price target of $305. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Wingstop, which currently sits at a price target of $375. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Overweight with a new price target of $450.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Wingstop with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

WING

Wingstop's Options: A Look at What the Big Money is Thinking

Citigroup analyst Jason Bazinet maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Neutral and raises the price target from $70 to $103.

ROKU

Citigroup Maintains Neutral on Roku, Raises Price Target to $103

Investors with a lot of money to spend have taken a bearish stance on Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RGTI, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 39 uncommon options trades for Rigetti Computing.
This isn't normal.
The overall sentiment of these big-money traders is split between 38% bullish and 56%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $421,533, and 33 are calls, for a total amount of $1,822,675.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $20.0 for Rigetti Computing over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Rigetti Computing's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Rigetti Computing's significant trades, within a strike price range of $5.0 to $20.0, over the past month.
<h3>Rigetti Computing Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740076235_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.4</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$20.00</td>
<td>$164.6K</td>
<td>926</td>
<td>165</td>
</tr>
<tr>
<td>RGTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.45</td>
<td>$1.4</td>
<td>$1.43</td>
<td>$10.00</td>
<td>$141.7K</td>
<td>5.5K</td>
<td>1.4K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.45</td>
<td>$1.4</td>
<td>$1.41</td>
<td>$13.00</td>
<td>$137.2K</td>
<td>5.4K</td>
<td>1.8K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.3</td>
<td>$1.25</td>
<td>$1.3</td>
<td>$14.00</td>
<td>$130.1K</td>
<td>3.9K</td>
<td>2.4K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$15.00</td>
<td>$129.6K</td>
<td>12.9K</td>
<td>563</td>
</tr>
</tbody>
</table>

<h3>About Rigetti Computing</h3>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.
Having examined the options trading patterns of Rigetti Computing, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Rigetti Computing Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 73,242,389, the RGTI's price is up by 2.18%, now at $11.27. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 21 days.</li>
</ul>
<h3>What The Experts Say On Rigetti Computing</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $15.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B. Riley Securities continues to hold a Buy rating for Rigetti Computing, targeting a price of $15. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Rigetti Computing, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

RGTI

Check Out What Whales Are Doing With RGTI

On Thursday, NetEase, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) reported a fiscal fourth-quarter revenue decline of 1.4% year-on-year to $3.66 billion (26.7&nbsp;billion Chinese yuan), missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43840713/netease-announces-fourth-quarter-and-fiscal-year-2024-unaudited-financial-results" rel="noreferrer noopener">analyst consensus estimate of $3.74 billion</a>.
The Chinese gaming&nbsp;player's&nbsp;adjusted EPADS of $2.07 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.77</a>. The stock fell after the report.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43812289/wix-q4-earnings-beats-estimates-raises-2025-outlook-ai-powered-expansion-and-market-share-gains" rel="noreferrer noopener">Wix Q4 Earnings: EPS Beat, Issues Strong 2025 Outlook With Two Products Launch</a>
Segments and margins: Games and related value-added services revenues rose 1.5%&nbsp;year over year&nbsp;to $2.9 billion.&nbsp;The corresponding gross margin decreased by 280 bps to 67.5%, mainly attributable to higher revenue contributions from licensed games, which have comparatively lower gross profit margins.
Youdao,&nbsp;Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) revenue declined by 9.5%&nbsp;year over year&nbsp;to $183.6 million,&nbsp;and&nbsp;the corresponding gross margin declined by 210 bps to 47.8%, primarily due to decreased net revenues from its&nbsp;learning services.
Cloud&nbsp;Music's&nbsp;revenues were $257.6 million, down 5.3% year over year, and its gross margin expanded by 160 bps to 31.9%, mainly due to increased net revenues from sales of membership subscriptions and continued improvement in cost control measures.
Innovative businesses and other revenue declined 17.0%&nbsp;year over year&nbsp;to $313.1 million, and the gross margin increased by 340 bps to 37.8%, mainly due to increased gross profit margins from Yanxuan.
As&nbsp;of December 31, 2024, NetEase held $18.0 billion in cash and equivalents and generated $1.78 billion in operating cash flow.
Dividend:&nbsp;The board of directors approved a dividend of&nbsp;$1.22025&nbsp;per ADS for the fourth quarter of 2024 versus $0.4350&nbsp;per ADS for the third quarter.
NetEase confirmed the laying off of the U.S.-based developers working on&nbsp;Marvel Rivals, the Verge <a target="_blank" href="https://www.theverge.com/news/615288/marvel-rivals-layoffs-netease-overseas-investments" rel="noreferrer noopener">cites</a> the company. However, the development of&nbsp;Rivals&nbsp;would continue with a core group of developers based in China.
Price Action: NTES stock is down 5.91% at $98.01 at&nbsp;the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43812509/garmin-q4-earnings-wearables-and-adventure-watches-drive-growth-raises-dividend-20-projects-68-billion-revenue-for-2025" target="_blank" rel="noreferrer noopener">Garmin Q4 Earnings: Wearables and Adventure Watches Drive Growth, 20% Dividend Hike, Stock Soars</a></li>
</ul>
Photo via Shutterstock

Dividends

Movers

Tech

Media

NTES

NetEase Q4 Earnings: Revenue Miss, Gaming and Cost Controls Drive Margins, Boosts Dividend

Maxim Group analyst Michael Okunewitch maintains Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) with a Buy and raises the price target from $4 to $7.

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
<h2>What are the Zacks Style Scores?</h2>
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
&nbsp;
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company&#39;s financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum investors, who live by the saying &quot;the trend is your friend,&quot; are most interested in taking advantage of upward or downward trends in a stock&#39;s price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It&#39;s a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
<h2>How Style Scores Work with the Zacks Rank</h2>
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company&#39;s earnings expectations, to help investors build a successful portfolio.
&nbsp;
Investors can count on the Zacks Rank&#39;s success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&amp;P 500&#39;s performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That&#39;s where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company&#39;s earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
<h2>Stock to Watch: RTX (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rtx#NYSE">RTX</a>)</h2>
In July 2023, Raytheon Technologies was renamed as RTX Corporation. On Apr 3, 2020, Raytheon Technologies was formed following the completion of merger between United Technologies and Raytheon Company. Based in Waltham, MA, Raytheon Technologies has emerged as an aerospace and defense company, with pro-forma combined annual revenues of $74 billion as of the end of 2019, providing advanced systems and services for commercial, military and government customers worldwide. Effective July 2023, the company operates through three business segments.
&nbsp;
RTX is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 20.48; value investors should take notice.
Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.06 to $6.13 per share. RTX boasts an average earnings surprise of 9.9%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, RTX should be on investors&#39; short list.
&nbsp;
<h2>Should You Invest in RTX Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rtx#NYSE">RTX</a>)?</h2>
Before you invest in RTX Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rtx#NYSE">RTX</a>), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on <a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1473&amp;adid=SYND_BENZ_ZU_7BESTREPORTA_TALEOFTAPE_546_02202025_2418658&amp;cid=CS-BENZ-FT-tale_of_the_tape|zacks_education_value_score-2418658" style="font-weight:bold">the 7 best stocks</a> to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&amp;P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_TALEOFTAPE_546_2418658&amp;cid=CS-BENZ-FT-tale_of_the_tape|zacks_education_value_score-2418658" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=RTX&amp;ADID=SYND_BENZ_TCK_TALEOFTAPE_546_2418658_RTX&amp;cid=CS-BENZ-FT-tale_of_the_tape|zacks_education_value_score-2418658">RTX Corporation (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/rtx#NYSE">RTX</a>): Free Stock Analysis Report
<a href="https://www.zacks.com/stock/news/2418658/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-BENZ-FT-tale_of_the_tape|zacks_education_value_score-2418658">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Are You A Value Investor? This 1 Stock Could Be The Perfect Pick

It doesn&#39;t matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
<h2>What are the Zacks Style Scores?</h2>
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
&nbsp;
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock&#39;s true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
Growth investors are more concerned with a stock&#39;s future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying &quot;the trend is your friend.&quot; This investing style is all about taking advantage of upward or downward trends in a stock&#39;s price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It&#39;s also one of the best indicators to use with the Zacks Rank.
<h2>How Style Scores Work with the Zacks Rank</h2>
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company&#39;s earnings expectations, to help investors build a successful portfolio.
&nbsp;
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&amp;P 500&#39;s performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That&#39;s where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock&#39;s earnings estimate revisions should be a key factor when choosing which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
<h2>Stock to Watch: Exelixis (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>)</h2>
Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.
&nbsp;
EXEL is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. EXEL has a Growth Style Score of A, forecasting year-over-year earnings growth of 15.5% for the current fiscal year.
10 analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.31 to $2.31 per share. EXEL also boasts an average earnings surprise of 26.9%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, EXEL should be on investors&#39; short list.
&nbsp;
<h2>Should You Invest in Exelixis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>)?</h2>
Before you invest in Exelixis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on <a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1473&amp;adid=SYND_BENZ_ZU_7BESTREPORTA_TALEOFTAPE_547_02202025_2418703&amp;cid=CS-BENZ-FT-tale_of_the_tape|zacks_education_growth_score-2418703" style="font-weight:bold">the 7 best stocks</a> to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&amp;P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_TALEOFTAPE_547_2418703&amp;cid=CS-BENZ-FT-tale_of_the_tape|zacks_education_growth_score-2418703" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EXEL&amp;ADID=SYND_BENZ_TCK_TALEOFTAPE_547_2418703_EXEL&amp;cid=CS-BENZ-FT-tale_of_the_tape|zacks_education_growth_score-2418703">Exelixis, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>): Free Stock Analysis Report
<a href="https://www.zacks.com/stock/news/2418703/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-BENZ-FT-tale_of_the_tape|zacks_education_growth_score-2418703">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

EXEL

Are You A Growth Investor? This 1 Stock Could Be The Perfect Pick

Ladenburg Thalmann analyst Jeff Cohen initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Buy rating and announces Price Target of $31.

Initiation

BBNX

Ladenburg Thalmann Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $31

The natural foods industry has evolved from a niche market into a mainstream sector, thanks to growing health consciousness and environmental awareness among consumers. With an increasing focus on clean eating, sustainability and ethical sourcing, natural and organic food products have rapidly gained popularity. As consumers seek products that align with their health goals, ethical farming practices and environmentally friendly production methods have become integral to the natural food movement.
Consumers are gravitating toward products that offer transparency in sourcing and minimal processing. Shoppers are scrutinizing ingredient labels, favoring organic, non-GMO (genetically modified organisms) and preservative-free options. Governments worldwide are also promoting clean eating and stricter food labeling regulations, further driving market expansion. As a result, natural food companies are seeing stronger brand loyalty and the ability to command premium pricing.
Companies like The Hain Celestial Group, Inc. HAIN and Vital Farms, Inc. VITL are responding to the rising demand for organic, clean-label and ethically sourced foods. With consumers prioritizing transparency, sustainability and minimal processing, the market for natural foods continues to grow. Expanding farm networks, plant-based innovations and a focus on humane, eco-friendly production are shaping the industry&#39;s future.
The natural foods industry is set to evolve with continuous innovation and expanding product categories. Companies are investing in plant-based alternatives, functional foods enriched with vitamins and probiotics, and sustainable farming technologies. E-commerce is also playing a crucial role in making natural foods more accessible, allowing consumers to shop for organic and gluten-free products with ease. The global <a href="https://www.globenewswire.com/news-release/2025/02/06/3021672/0/en/Global-Healthy-Foods-Market-to-Reach-USD-2-264-1-Billion-by-2035-Growing-at-a-9-7-CAGR-Future-Market-Insights-Inc.html" target="_blank">healthy foods market</a> is expected to reach $2.26 trillion by 2035.&nbsp;
If you&#39;re looking to capitalize on this trend, our <a href="https://www.zacks.com/screening/thematic-screens/screen-details/132/natural-foods">Natural Foods Screen</a> makes it easy to identify high-potential stocks such as United Natural Foods, Inc. UNFI, Sprouts Farmers Market, Inc. SFM and Beyond Meat, Inc. BYND.
Explore 30 cutting-edge investment themes with <a href="https://www.zacks.com/screening/thematic-screens/?icid=screening-screening-nav_tracking-zcom-main_menu_wrapper-thematic_screens">Zacks Thematic Screens</a> and uncover your next big opportunity.
<h2>3 Natural Foods Stocks to Watch</h2>
<a href="https://www.zacks.com/stock/news/2415391/is-united-natural-foods-unfi-outperforming-other-consumer-staples-stocks-this-year">United Natural</a> stands as a prominent player in the natural foods sector, serving as one of the largest distributors of organic and natural products in North America. Through its extensive network, UNFI supplies a vast array of products, including fresh produce, pantry staples, dairy alternatives and plant-based foods. With its diverse portfolio, the company caters to both retail giants and independent natural food stores, meeting the growing demand for cleaner, healthier eating options.
As the natural foods industry continues to expand, UNFI is well-positioned to capitalize on the shift toward organic, non-GMO and ethically sourced products. Its wide-reaching distribution capabilities and strategic partnerships allow the company to provide an extensive selection of natural and organic foods that appeal to health-conscious consumers. The company&#39;s natural business continues to outperform industry trends, driven by strong volume growth and enhanced supplier collaborations.&nbsp;
This Zacks Rank #2 (Buy) company is increasingly focusing on innovation and sustainability within the natural foods space. The company has committed to enhancing its supply-chain practices, reducing waste and supporting regenerative agriculture initiatives. UNFI is also working closely with suppliers to accelerate food innovation. Through its supplier go-to-market program, the company has simplified the process of bringing new natural and organic products to store shelves. This initiative has enabled suppliers to reintroduce thousands of SKUs that were previously discontinued, expanding consumer access to diverse and healthier food options. You can see <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the complete list of today&#39;s Zacks #1 Rank (Strong Buy) stocks here</a>.
<a href="https://www.zacks.com/stock/news/2416746/is-sprouts-farmers-stock-a-smart-buy-before-q4-earnings-report">Sprouts Farmers</a> has been at the forefront of the natural and organic food movement, catering to health-conscious consumers seeking fresh, high-quality and ethically sourced products. The company&#39;s commitment to fresh, organic and attribute-driven products sets it apart. With nearly 46% of total produce sales now coming from organic products, SFM continues to expand its assortment, ensuring accessibility to high-quality, responsibly sourced food.
A key element of SFM&#39;s strategy is its innovative product development and sourcing initiatives. Notable offerings include organic grass-fed meatballs, pasture-raised poultry and globally inspired Sprouts-branded items, such as Moroccan and al pastor-flavored chickpeas. These exclusive, trend-forward products cater to the evolving preferences of health-conscious consumers.
This Zacks Rank #2 company continues to strengthen its connection with customers through tailored marketing and engagement efforts, such as social media campaigns and in-store discovery events like Sprouts Brand Discovery Days. These initiatives showcase the company&#39;s differentiated offerings while attracting a younger demographic and increasing foot traffic.
<a href="https://www.zacks.com/stock/news/2417375/top-ag-tech-food-innovation-stocks-in-focus-right-now">Beyond Meat</a> is transforming plant-based food by using cleaner, healthier ingredients. The company&#39;s latest Beyond 4 products, including the Beyond Burger and Beyond Beef, are made from a blend of yellow peas, brown rice, red lentils and fava beans. These ingredients provide 21 grams of protein per serving while cutting saturated fat by 75% compared to traditional beef burgers, thanks to the use of avocado oil. This commitment to nutrition has earned recognition from the American Diabetes Association and the American Heart Association, reinforcing Beyond Meat&#39;s focus on making plant-based options both tasty and healthy.
Beyond Meat is also expanding its product range to meet evolving consumer tastes. The introduction of Beyond Sun Sausage marks a significant departure from conventional meat alternatives, embracing a new category of plant-based protein not modeled after beef, pork or poultry. This product, packed with 12 grams of protein and just 1 gram of saturated fat from avocado oil, has received strong endorsements for its clean-label approach. Furthermore, the company has unveiled Beyond Steak Filet, a whole-muscle alternative crafted from mycelium, the root-like structure of mushrooms, along with legume proteins.&nbsp;
This Zacks Rank #3 (Hold) company&#39;s commitment to food innovation extends beyond retail into food service partnerships. The reintroduction of Beyond The Original Orange Chicken at Panda Express and the expansion of Beyond Nuggets at McDonald&#39;s locations in Europe underscore its ability to integrate healthier, plant-based options into mainstream dining. At the same time, Beyond Meat is working to educate consumers on its clean-label approach, challenging misconceptions about plant-based food processing.
&nbsp;
<h2>5 Stocks Set to Double</h2>
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1726&amp;adid=SYND_BENZ_ZU_5S2DREPORT_ANALYSTBLOG_215_IND_02202025_2418548&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2418548" style="font-weight:bold">Today, See These 5 Potential Home Runs &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ANALYSTBLOG_215_2418548&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2418548" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=HAIN&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2418548_HAIN&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2418548">The Hain Celestial Group, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/hain#NASDAQ">HAIN</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=UNFI&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2418548_UNFI&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2418548">United Natural Foods, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/unfi#NASDAQ">UNFI</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=SFM&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2418548_SFM&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2418548">Sprouts Farmers Market, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/sfm#NASDAQ">SFM</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=BYND&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2418548_BYND&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2418548">Beyond Meat, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=VITL&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2418548_VITL&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2418548">Vital Farms, Inc. (VITL): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/stock/news/2418548/3-natural-foods-stocks-positioned-for-success-in-2025?cid=CS-BENZ-FT-analyst_blog|investment_ideas-2418548">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

BYND

HAIN

UNFI

3 Natural Foods Stocks Positioned For Success In 2025

Lake Street analyst Ben Haynor maintains Lifeward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) with a Buy and lowers the price target from $6 to $4.5.

LFWD

Lake Street Maintains Buy on Lifeward, Lowers Price Target to $4.5

Celanese Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares are trading lower on Thursday after several analysts slashed price forecasts following fourth-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/CE/analyst-ratings" rel="noreferrer noopener">earnings&nbsp;reported on Tuesday</a>.&nbsp;
Celanese reported adjusted earnings per share of $1.45, beating analysts' estimate of $1.20 and sales of $2.37 billion, which came&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/02/43830036/whats-going-on-with-celanese-shares-wednesday" target="_blank" rel="noreferrer noopener">in line with analysts' estimates</a>.
The company issued guidance for the 2025&nbsp;first-quarter. It sees earnings per share from 25 cents to 50 cents, versus analysts'&nbsp;estimate&nbsp;of $1.63.
Celanese expects its 2025 second-quarter earnings per share to be about&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$1 higher than in the first quarter</a>.&nbsp;
JPMorgan analyst Jeffrey J. Zekauskas lowered the price forecast from $92 to $54 with a Neutral rating.
The analyst writes that Celanese is facing simultaneous challenges in earnings, cash flow, and credit.&nbsp;
The company has exposure to the automotive industry in Europe and the U.S., where demand is expected to remain flat. 
Zekauskas says that the Acetyl Chain segment may experience pricing pressure in 2025, as lower spot pricing in 2024 impacts large customer contract resets.&nbsp;
Additionally, the new acetic acid capacity in China could exert downward pressure on pricing in the medium to long term, adds the analyst.
The analyst says he recommends waiting for greater earnings stability and predictability.&nbsp;
As a result, Zekauskas revised the 2025 EPS forecast down to $6.30 from $9.05.
Other&nbsp;analyst&#8217;s&nbsp;price forecast/rating revisions include:
<ul>
<li>Baird&nbsp;analyst Ghansham Panjabi maintained an Outperform rating and lowered the price forecast from&nbsp;$110&nbsp;to&nbsp;$67.</li>
<li>Wells Fargo&nbsp;analyst Michael Sison reiterated an Equal-Weight rating and cut the price forecast from&nbsp;$75&nbsp;to&nbsp;$55.</li>
<li>UBS&nbsp;analyst analyst Joshua Spector kept Neutral and lowered the price forecast from&nbsp;$72&nbsp;to&nbsp;$60.</li>
<li>Deutsche Bank&nbsp;analyst David Begleiter maintained a Buy rating and slashed the price forecast from&nbsp;$85&nbsp;to&nbsp;$70.</li>
<li>RBC Capital&nbsp;analyst Arun Viswanathan downgraded the company from Outperform to Sector Perform and lowered the price forecast from&nbsp;$84&nbsp;to&nbsp;$56.</li>
</ul>
Investors can gain exposure to the stock via&nbsp;First Trust Materials AlphaDEX Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXZ#NYSE">FXZ</a>) and&nbsp;Pacer CFRA-Stovall Equal Weight Seasonal Rotation ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SZNE#NYSE">SZNE</a>).
Price Action: CE shares are down 5.04% at $52.15 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43856681" target="_blank" rel="noreferrer noopener">Bloom Energy Strengthens 10-Year Equinix Partnership, Deploying Next-Gen Fuel Cells For Data Center Power</a></li>
</ul>
Image: Shutterstock

Mid Cap

Downgrades

Pacer CFRA-Stovall Equal Weight Seasonal Rotation ETF

SZNE

Celanese Analysts Brace For Tough 2025 As Price Cuts Pile Up

Financial giants have made a conspicuous bullish move on American Airlines Gr. Our analysis of options history for American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) revealed 12 unusual trades.
Delving into the details, we found 75% of traders were bullish, while 16% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $659,484, and 6 were calls, valued at $253,396.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $12.0 to $20.0 for American Airlines Gr over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for American Airlines Gr options trades today is 12927.73 with a total volume of 8,639.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for American Airlines Gr's big money trades within a strike price range of $12.0 to $20.0 over the last 30 days.
<h3>American Airlines Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740075339_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$0.59</td>
<td>$0.53</td>
<td>$0.54</td>
<td>$12.00</td>
<td>$172.8K</td>
<td>1.1K</td>
<td>3.2K</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.89</td>
<td>$1.85</td>
<td>$1.86</td>
<td>$15.00</td>
<td>$148.8K</td>
<td>22.9K</td>
<td>800</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$4.95</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$20.00</td>
<td>$143.5K</td>
<td>6.8K</td>
<td>296</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$0.97</td>
<td>$0.94</td>
<td>$0.95</td>
<td>$15.00</td>
<td>$123.5K</td>
<td>5.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>AAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.66</td>
<td>$2.63</td>
<td>$2.67</td>
<td>$14.00</td>
<td>$53.4K</td>
<td>482</td>
<td>1</td>
</tr>
</tbody>
</table>

<h3>About American Airlines Gr</h3>
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of US legacy carriers.
In light of the recent options history for American Airlines Gr, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>American Airlines Gr's Current Market Status</h3>
<ul>
<li>Trading volume stands at 17,170,408, with AAL's price down by -0.25%, positioned at $15.96.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 63 days.</li>
</ul>
<h3>What The Experts Say On American Airlines Gr</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Neutral rating on American Airlines Gr with a target price of $18. 
&#x2A; In a cautious move, an analyst from Raymond James downgraded its rating to Outperform, setting a price target of $23. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for American Airlines Gr, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Comments

XS Financial Inc

XS Financial Inc (XSHLF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga